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Type I interferon (IFN) production by innate immune cells
is critical to prime spontaneous T cell responses against
solid tumors. Emerging pre-clinical data suggests that
tumor-derived DNA induces potent IFN-b production by
activating a cytosolic DNA sensing receptor called STING
(Stimulator of Interferon Genes), ultimately resulting in
tumor antigen-specific T cell priming and in some cases,
tumor rejection. However, because of their disseminated
growth pattern, hematological malignancies, such as acute
myeloid leukemia (AML), may not release sufficient quanti-
ties of DNA during cell death to activate the STING path-
way in innate immune cells, which contributes to the T cell
tolerance observed in these hosts. Thus, we hypothesized
that STING pathway activation would promote a host type
I IFN response sufficient to facilitate leukemia-specific
T cell priming and immune-mediated control of AML pro-
gression. Murine C1498 AML cells expressing the model
SIY antigen (C1498.SIY) were inoculated intravenously into
syngeneic C57BL/6 mice which then received a single dose
of the murine STING agonist, DMXAA (5,6-dimethyl-
xanthenone-4-acetic acid), or vehicle control 5 days later.
DMXAA induced potent IFN-b production by C57BL/6
spleen cells (90-fold induction over vehicle control).
STING pathway activation via DMXAA treatment of
C1498.SIY-bearing animals resulted in a massive expansion
(10-fold over vehicle control) of endogenous SIY antigen-
specific T cells as analyzed by SIY/Kb pentamer staining
and flow cytometry. Intracellular cytokine staining of SIY-
peptide restimulated spleen cells from DMXAA-treated
animals revealed that the expanded SIY-specific CD8+ T
cells produced high-levels of IFN-g. This enhanced immune
response also translated to a benefit in survival. After
C1498.SIY AML cell-challenge, 80% of DMXAA-treated
mice survived long-term, while controls succumbed to
AML within approximately 3-4 weeks, as expected.
DMXAA-treated mice surviving a primary C1498.SIY cell
challenge also rejected a secondary challenge with parental
C1498 cells (SIY-negative), suggesting DMXAA-induced
STING activation led to potent immunological memory
against native C1498-expressed antigens. DMXAA treat-
ment of mice following a systemic challenge with parental
C1498 cells also led to significantly enhanced survival com-
pared to control-treated animals. This effect was T and/or
B cell-dependent, as DMXAA treatment of leukemia-
bearing RAG-/- mice had no effect on survival. Collectively,
these data suggest that DMXAA-mediated activation of the
STING pathway enhances adaptive immunity to AML, cul-
minating in prolonged survival and even disease cure.
Human STING agonists are currently in development and,
if STING pathway activation demonstrates efficacy in addi-
tional pre-clinical leukemia models, it may be of interest to
target this pathway in AML patients.
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